Rigor Reviewed

Rigor-Reviewed Manuscript

Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.

Name: Αlpha¹ Rigor Record — Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Item: Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Rating: 96
Author: Αlpha¹

Gallagher KE, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, Mwalekwa L, Ragab S, Twi-Yeboah L, Berkley JA, Hamaluba M, Karani A, Shangala J, Otiende M, Gardiner E, Mugo D, Smith PG, Tabu C, Were F, Goldblatt D, Scott JAG

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.5★ (Weak), 0 critical, 2 high issues for “Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.5 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★
LinksDead data/code link−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Dead data/code linksRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized non-inferiority trial with rigorous design, clear ethical approvals, and transparent reporting. The main weakness is the vague data availability statement and lack of code sharing, which limits reproducibility. Minor copyedit issues and a dead link in the reproducibility check are also noted.

Both reviewers classified the study as interventional, and no divergence was noted. The evaluation covered the full text, with verification components checking citations (43 references, none flagged), statistics (0 tests recomputable), reproducibility (1 dead link), and preregistration (ClinicalTrials.gov). Non-applicable sub-criteria (e.g., animal housing, cell lines) were excluded.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior trials of fractional doses for other vaccines and a systematic review of a pentavalent PCV, and acknowledges the cost burden of PCVs in LMICs. The rationale linking the premise to the study objectives is explicit. Limitations of prior research are addressed by noting the need for a dedicated trial of fractional PCV doses.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work and a logical rationale for testing fractional doses of PCV.

Evidence

paraphrase[Introduction, paragraph 2]

“Fractional doses of antigen have been shown to induce non-inferior immune responses to full doses in trials of vaccines against Haemophilus influenzae type b (Hib), Neisseria meningitidis, Yellow Fever and Polio.”

direct quote[Introduction, paragraph 3]

“We aimed to assess whether the serotype-specific immunogenicity of fractional doses (20% or 40%) of PCV10 or PCV13, administered in a 2p+1 schedule, was non-inferior to the immunogenicity of full doses.”